Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Recruiting, any sponsor type, condition "Gaucher"
By trial status
The same filters, counted in each status. Pick one to switch.
7 trials
Showing 1 to 7, recently updated first.
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT03721068 · 18 participants (planned) · Start Feb 19, 2019 · Primary completion May 19, 2030
Drug: iC9.GD2.CAR.IL-15 T-cells; Cyclophosphamide and 1 more · For: Neuroblastoma; Osteosarcoma
Sites: Atlanta, Georgia; Chapel Hill, North Carolina
University of California, San FranciscoAcademic, hospital or other
NCT04532047 · 10 participants (planned) · Start Jul 1, 2021 · Primary completion Jul 31, 2031
Drug: Aldurazyme (laronidase) · For: MPS I; MPS II; MPS IVA and 6 more
Sites: San Francisco, California
University of PittsburghAcademic, hospital or other
NCT03333200 · 1,500 participants (planned) · Start Jan 11, 2012 · Primary completion Jan 2030
Drug: Hematopoetic Stem Cell Transplantation · For: MLD; Krabbe Disease; ALD and 24 more
Sites: Pittsburgh, Pennsylvania
Paul SzabolcsAcademic, hospital or other
NCT04528355 · 50 participants (planned) · Start Aug 20, 2020 · Primary completion Dec 31, 2027
Drug: data collection · For: Primary Immunodeficiency (PID); Congenital Bone Marrow Failure Syndromes; Inherited Metabolic Disorders (IMD) and 2 more
Sites: Pittsburgh, Pennsylvania
Paul SzabolcsAcademic, hospital or other
NCT01962415 · 100 participants (planned) · Start Feb 4, 2014 · Primary completion Nov 2026
Drug: Hydroxyurea; Alemtuzumab and 3 more · For: Primary Immunodeficiency (PID); Congenital Bone Marrow Failure Syndromes; Inherited Metabolic Disorders (IMD) and 4 more
Sites: Pittsburgh, Pennsylvania
He HuangAcademic, hospital or other
NCT06162338 · 3 participants (planned) · Start Nov 15, 2023 · Primary completion Dec 17, 2026
Drug: LY-M001 Injection · For: Gaucher Disease Type I
Sites: Hanzhou, China
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT06272149 · 6 participants (planned) · Start Mar 1, 2023 · Primary completion Jan 15, 2025
Drug: VGN-R08b · For: Type II Gaucher Disease
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.